Wearables in Pharma & Biotech Market worth $9.97 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., April 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Wearables in Pharma & Biotech Market is projected to grow from about USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%.

Browse 531 market data Tables and 54 Figures spread through 457 Pages and in-depth TOC on 'Wearables in Pharma & Biotech Market- Global Forecast to 2031'

Wearables in Pharma & Biotech Market Size & Forecast:

• Market Size Available for Years: 2025–2031
• 2026 Market Size: USD 3.98 billion
• 2031 Projected Market Size: USD 9.97 billion
• CAGR (2026–2031): 20.2%

Wearables in Pharma & Biotech Market Trends & Insights:

• In 2025, the continuous glucose monitor (CGM) segment accounted for 31.3% of the wearables in pharma & biotech market.
• Pharmaceutical & biotech companies accounted for the largest share (53.5%) of the wearables in pharma & biotech market in 2025.
• North America accounted for the largest share (42.3%) of the global wearables in pharma & biotech market in 2025.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=99537956

The market is gaining traction as the healthcare industry, governments, and pharma companies are adopting this technology to deliver better patient outcomes and successful clinical trials. The rise of decentralized and hybrid trials, which have been endorsed by the FDA in the US, is contributing to the growing use of wearables in the clinical research industry. This technology enhances the efficiency of conducting clinical trials and engaging patients. According to a research article published by PLOS Digital Health, 85% of studies utilizing wearables focus on monitoring patients with chronic diseases, with neurodegenerative diseases being the most prevalent. Additionally, 15% of studies are aimed at diagnosing diseases, primarily focusing on cardiovascular conditions. Notably, watches and bracelets represent 63% of the wearables employed in these studies. Even though only 8% of the studies were randomized trials, 67% showed clinical impact. However, according to the evidence provided by BMJ, the wearables used in clinical trials help in solving the challenges in this industry, and there are other aspects that need to be improved.

By therapeutic area, diabetes segment to register fastest growth during forecast period.

The diabetes segment is anticipated to show the highest growth rate in the wearables in pharma & biotech market during the forecast period. This is mainly because of the high rate of growth in the global diabetes population and the need for constant monitoring. According to the International Diabetes Federation (IDF) update of 2024, there are 589 million adults worldwide with diabetes mellitus. The numbers are projected to rise to over 850 million adults worldwide by 2050. This clearly indicates that there is a high rate of growth in the global population with diabetes. In the US, there are over 38 million people with diabetes, and nearly 1 in 3 adults has prediabetes. This clearly indicates that there is a high population that needs to be monitored. The global health expenditure on diabetes exceeded USD 1 trillion in 2023.

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=99537956

By application, clinical trials segment held largest market share in 2025.

The clinical trials segment accounted for the largest share of the wearables in pharma & biotech industry in 2025. This is due to the increased need for efficient, patient-centric, and high-data-content study designs. According to the US Food and Drug Administration, there is increased focus on digital health technologies, such as wearables, in supporting decentralized clinical trials. In 2023, the Tufts Center for the Study of Drug Development found that the average cost of developing a new drug is above USD 2.6 billion. This is encouraging pharma companies to use wearable-enabled monitoring in order to decrease the cost of clinical trials. According to Nature Medicine publications, there is an increased chance of collecting data as often as required by using wearable devices in comparison to conventional site-based methods of collecting endpoint data. All these factors are resulting in the dominance of the clinical trials segment in the wearables in pharma & biotech industry.

North America accounted for largest market share in 2025.

North America accounted for the largest share of the global wearables in pharma & biotech market in 2025, given its high rate of adoption of connected health technologies and high integration of patient-generated data. According to PubMed Central research on wearables and health data, 44.5% of 23,974 respondents used wearables, and this rate was higher among younger people and people from urban and high-income areas. This suggests that there is a high consumer base that is generating continuous real-world health data for pharma and biotech use. North America is also benefiting from its high rate of innovation in wearables and other pharma and biotech technologies. For instance, there is significant funding and research support from institutions such as the National Institutes of Health and the National Science Foundation to support biosensors and other wearables and digital health technologies. Furthermore, there is reimbursement support for remote patient monitoring from the Centers for Medicare & Medicaid Services, which is further boosting the use of wearables and other integrated healthcare technologies in the region.

Inquire Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=99537956

Top Companies in Wearables in Pharma & Biotech Market:

The Top Companies in Wearables in Pharma & Biotech Market include BD (US), Abbott (US), Masimo (US), Apple Inc. (US), DexCom, Inc. (US), Medtronic (Ireland), iRhythm Technologies, Inc. (US), BioIntelliSense, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), BioBeat Technologies Ltd. (Israel), Empatica Inc. (US), VitalConnect, Inc. (US), Ametris LLC (US), AliveCor, Inc. (US), Boston Scientific Corporation (US), Withings S.A. (France), VivaLNK, Inc. (US), and MediBioSense Ltd. (UK).

Browse Adjacent Markets: Healthcare IT Market Research Reports & Consulting

Related Reports:

Wearable Healthcare Devices Market - Global Forecast to 2030

Medical Device Connectivity Market - Global Forecast to 2028

Clinical Trial Services Market - Global Forecast to 2030        

Home Healthcare Market - Global Forecast to 2030

Diabetes Care Devices Market - Global Forecast to 2030

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg